Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market 2024-2028

Description

List of Tables

The PARP (Poly ADP-ribose Polymerase) inhibitors market is forecasted to grow by USD 5555.99 mn during 2023-2028, accelerating at a CAGR of 13.25% during the forecast period. The report on the PARP (Poly ADP-ribose Polymerase) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the expanded application of PARP inhibitors, ease of administration for treatment of various cancer indications, and increasing patient assistance programs.

Technavio's PARP (Poly ADP-ribose Polymerase) inhibitors market is segmented as below:

Market Scope
Base Year	2022
End Year	2027
Series Year	2023-2027
Growth Momentum	Accelerate
YOY 2023	12.75%
CAGR	13.25%
Incremental Value	$5555.99mn

By Distribution Channel

Retail pharmacies
Hospital pharmacies
Online pharmacies

By End-user

Ovarian cancer
Breast cancer
Others

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the extensive ongoing research as one of the prime reasons driving the PARP (Poly ADP-ribose Polymerase) inhibitors market growth during the next few years. Also, growing prevalence of cancer and new research areas in human genes will lead to sizable demand in the market.

The report on the PARP (Poly ADP-ribose Polymerase) inhibitors market covers the following areas:

Parp (Poly ADP-ribose Polymerase) inhibitors market sizing
Parp (Poly ADP-ribose Polymerase) inhibitors market forecast
Parp (Poly ADP-ribose Polymerase) inhibitors market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading PARP (Poly ADP-ribose Polymerase) inhibitors market vendors that include AbbVie Inc., Allarity Therapeutics Inc., Artios Pharma, AstraZeneca Plc, Bayer AG, BeiGene Ltd., Daiichi Sankyo Co. Ltd., Everest Pharmaceuticals Ltd., GlaxoSmithKline Plc, IMPACT Therapeutics, Jeil Pharmaceuticals Co. Ltd., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Johnson and Johnson, Karyopharm Therapeutics Inc., Merck and Co. Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Repare Therapeutics Inc., Teva Pharmaceutical Industries Ltd., and Zai Lab Ltd.. Also, the parp (Poly ADP-ribose Polymerase) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR43323

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibit 06: Executive Summary - Chart on Market Segmentation by End-user
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global PARP (poly ADP-ribose polymerase) inhibitors market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global parp (poly adp-ribose polymerase) inhibitors market 2018 - 2022 ($ million)
4.2 Distribution Channel Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
4.3 End-user Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - End-user Segment 2018 - 2022 ($ million)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Distribution Channel

6.1 Market segments
Exhibit 30: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibit 31: Data Table on Distribution Channel - Market share 2023-2028 (%)
6.2 Comparison by Distribution Channel
Exhibit 32: Chart on Comparison by Distribution Channel
Exhibit 33: Data Table on Comparison by Distribution Channel
6.3 Retail pharmacies - Market size and forecast 2023-2028
Exhibit 34: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 35: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 36: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
6.4 Hospital pharmacies - Market size and forecast 2023-2028
Exhibit 38: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 39: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 40: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
6.5 Online pharmacies - Market size and forecast 2023-2028
Exhibit 42: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 43: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 44: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 45: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
6.6 Market opportunity by Distribution Channel
Exhibit 46: Market opportunity by Distribution Channel ($ million)
Exhibit 47: Data Table on Market opportunity by Distribution Channel ($ million)

7 Market Segmentation by End-user

7.1 Market segments
Exhibit 48: Chart on End-user - Market share 2023-2028 (%)
Exhibit 49: Data Table on End-user - Market share 2023-2028 (%)
7.2 Comparison by End-user
Exhibit 50: Chart on Comparison by End-user
Exhibit 51: Data Table on Comparison by End-user
7.3 Ovarian cancer - Market size and forecast 2023-2028
Exhibit 52: Chart on Ovarian cancer - Market size and forecast 2023-2028 ($ million)
Exhibit 53: Data Table on Ovarian cancer - Market size and forecast 2023-2028 ($ million)
Exhibit 54: Chart on Ovarian cancer - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on Ovarian cancer - Year-over-year growth 2023-2028 (%)
7.4 Breast cancer - Market size and forecast 2023-2028
Exhibit 56: Chart on Breast cancer - Market size and forecast 2023-2028 ($ million)
Exhibit 57: Data Table on Breast cancer - Market size and forecast 2023-2028 ($ million)
Exhibit 58: Chart on Breast cancer - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Breast cancer - Year-over-year growth 2023-2028 (%)
7.5 Others - Market size and forecast 2023-2028
Exhibit 60: Chart on Others - Market size and forecast 2023-2028 ($ million)
Exhibit 61: Data Table on Others - Market size and forecast 2023-2028 ($ million)
Exhibit 62: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibit 63: Data Table on Others - Year-over-year growth 2023-2028 (%)
7.6 Market opportunity by End-user
Exhibit 64: Market opportunity by End-user ($ million)
Exhibit 65: Data Table on Market opportunity by End-user ($ million)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 67: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 68: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 69: Chart on Geographic comparison
Exhibit 70: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 UK - Market size and forecast 2023-2028
Exhibit 91: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 92: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 93: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.9 Canada - Market size and forecast 2023-2028
Exhibit 95: Chart on Canada - Market size and forecast 2023-2028 ($ million)
Exhibit 96: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
Exhibit 97: Chart on Canada - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on Canada - Year-over-year growth 2023-2028 (%)
9.10 Germany - Market size and forecast 2023-2028
Exhibit 99: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 100: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 101: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.11 China - Market size and forecast 2023-2028
Exhibit 103: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibit 104: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibit 105: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 106: Data Table on China - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 107: Market opportunity By Geographical Landscape ($ million)
Exhibit 108: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 109: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 111: Overview on factors of disruption
11.4 Industry risks
Exhibit 112: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 113: Vendors covered
12.2 Market positioning of vendors
Exhibit 114: Matrix on vendor position and classification
12.3 AbbVie Inc.
Exhibit 115: AbbVie Inc. - Overview
Exhibit 116: AbbVie Inc. - Product / Service
Exhibit 117: AbbVie Inc. - Key news
Exhibit 118: AbbVie Inc. - Key offerings
12.4 Allarity Therapeutics Inc.
Exhibit 119: Allarity Therapeutics Inc. - Overview
Exhibit 120: Allarity Therapeutics Inc. - Product / Service
Exhibit 121: Allarity Therapeutics Inc. - Key offerings
12.5 AstraZeneca Plc
Exhibit 122: AstraZeneca Plc - Overview
Exhibit 123: AstraZeneca Plc - Product / Service
Exhibit 124: AstraZeneca Plc - Key news
Exhibit 125: AstraZeneca Plc - Key offerings
12.6 Bayer AG
Exhibit 126: Bayer AG - Overview
Exhibit 127: Bayer AG - Business segments
Exhibit 128: Bayer AG - Key news
Exhibit 129: Bayer AG - Key offerings
Exhibit 130: Bayer AG - Segment focus
12.7 BeiGene Ltd.
Exhibit 131: BeiGene Ltd. - Overview
Exhibit 132: BeiGene Ltd. - Business segments
Exhibit 133: BeiGene Ltd. - Key offerings
Exhibit 134: BeiGene Ltd. - Segment focus
12.8 Daiichi Sankyo Co. Ltd.
Exhibit 135: Daiichi Sankyo Co. Ltd. - Overview
Exhibit 136: Daiichi Sankyo Co. Ltd. - Product / Service
Exhibit 137: Daiichi Sankyo Co. Ltd. - Key news
Exhibit 138: Daiichi Sankyo Co. Ltd. - Key offerings
12.9 Everest Pharmaceuticals Ltd.
Exhibit 139: Everest Pharmaceuticals Ltd. - Overview
Exhibit 140: Everest Pharmaceuticals Ltd. - Product / Service
Exhibit 141: Everest Pharmaceuticals Ltd. - Key offerings
12.10 GlaxoSmithKline Plc
Exhibit 142: GlaxoSmithKline Plc - Overview
Exhibit 143: GlaxoSmithKline Plc - Business segments
Exhibit 144: GlaxoSmithKline Plc - Key news
Exhibit 145: GlaxoSmithKline Plc - Key offerings
Exhibit 146: GlaxoSmithKline Plc - Segment focus
12.11 IMPACT Therapeutics
Exhibit 147: IMPACT Therapeutics - Overview
Exhibit 148: IMPACT Therapeutics - Product / Service
Exhibit 149: IMPACT Therapeutics - Key offerings
12.12 Jeil Pharmaceuticals Co. Ltd.
Exhibit 150: Jeil Pharmaceuticals Co. Ltd. - Overview
Exhibit 151: Jeil Pharmaceuticals Co. Ltd. - Product / Service
Exhibit 152: Jeil Pharmaceuticals Co. Ltd. - Key offerings
12.13 Jiangsu Hengrui Pharmaceuticals Co. Ltd.
Exhibit 153: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Overview
Exhibit 154: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Product / Service
Exhibit 155: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Key offerings
12.14 Merck and Co. Inc.
Exhibit 156: Merck and Co. Inc. - Overview
Exhibit 157: Merck and Co. Inc. - Business segments
Exhibit 158: Merck and Co. Inc. - Key news
Exhibit 159: Merck and Co. Inc. - Key offerings
Exhibit 160: Merck and Co. Inc. - Segment focus
12.15 Ono Pharmaceutical Co. Ltd.
Exhibit 161: Ono Pharmaceutical Co. Ltd. - Overview
Exhibit 162: Ono Pharmaceutical Co. Ltd. - Product / Service
Exhibit 163: Ono Pharmaceutical Co. Ltd. - Key offerings
12.16 Pfizer Inc.
Exhibit 164: Pfizer Inc. - Overview
Exhibit 165: Pfizer Inc. - Product / Service
Exhibit 166: Pfizer Inc. - Key news
Exhibit 167: Pfizer Inc. - Key offerings
12.17 Zai Lab Ltd.
Exhibit 168: Zai Lab Ltd. - Overview
Exhibit 169: Zai Lab Ltd. - Product / Service
Exhibit 170: Zai Lab Ltd. - Key offerings

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 171: Inclusions checklist
Exhibit 172: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 173: Currency conversion rates for US$
13.4 Research methodology
Exhibit 174: Research methodology
Exhibit 175: Validation techniques employed for market sizing
Exhibit 176: Information sources
13.5 List of abbreviations
Exhibit 177: List of abbreviations